Lezutica monoclonal antibody, a dual-target drug targeting IL-17A/F by Lijiu Pharmaceuticals, has been accepted for market application for the treatment of ankylosing spondylitis.

On June 3rd, LIZHU Pharmaceuticals announced that the application for the market approval of the company's Class 1 innovative biological drug Lekankita monoclonal antibody for the treatment of ankylosing spondylitis has been officially accepted by the National Medical Products Administration.